Overview of Supran

Property	Description
Active ingredient	Dilazep (as dihydrochloride salt)
Form	Tablets, Capsules (Oral)
Pharmacological class	Coronary Vasodilator; Antiplatelet Agent (ATC C01DX)
Common use	Cardiovascular support
Origin	Synthetic organic compound

What Type of Medicine is Supran (Dilazep)?

Supran is a pharmaceutical preparation whose activity is centered on the synthetic chemical compound Dilazep, specifically its dihydrochloride salt. It is classified under the Anatomical Therapeutic Chemical (ATC) system as C01DX10, positioning it as an Other Vasodilator Used in Cardiac Diseases. This places Supran in the high-level category of drugs intended for cardiac therapy. Dilazep is chemically recognized as a homopiperazine derivative and a benzoate diester, reflecting its specialized, synthesized structure. Unlike many older agents that act directly on smooth muscle, Dilazep has been clinically recognized for its specific mechanism as an adenosine reuptake inhibitor.

Composition and Available Pharmaceutical Forms

The core composition relies entirely on the pharmacological properties of Dilazep, which inhibits the membrane transport of nucleosides. As a drug designed for systemic effects, Supran is intended for oral administration, and is generally supplied in the form of tablets or capsules. The preparation utilizes the active Dilazep substance alongside necessary inert carriers to create a stable, solid dosage form for ingestion. This focus on a single, well-defined compound, rather than a combination of multiple active ingredients, is a key compositional feature.

What is the General Therapeutic Purpose of Supran?

The general therapeutic purpose of Supran is to support cardiovascular function by influencing coronary circulation and blood flow characteristics. As a potent vasodilator agent, the drug helps to increase the supply of blood and oxygen to the heart muscle. Dilazep’s primary effect is as an adenosine reuptake inhibitor, which promotes vasodilation and antiplatelet activity. Furthermore, Dilazep exhibits actions as a platelet aggregation inhibitor, contributing to maintaining healthy blood flow and supporting the overall balance of the cardiac system, a benefit that distinguishes it from pure vasodilators.

What side effects are possible with Supran?

Possible Side Effects and Safety Information

The safety profile for Supran (Dilazep) is established through official regulatory documentation, classifying potential adverse reactions by frequency and affected organ system. This structure provides a neutral assessment of the medicine’s safety characteristics, distinguishing between common and rare occurrences.

Adverse Reactions and Frequencies

Adverse reactions are formally grouped into categories based on reporting frequency, which primarily involve the Gastrointestinal and Nervous Systems.

Classification	Examples of Documented Adverse Reactions
Common	Nausea, Stomach discomfort, Malaise
Uncommon	Dizziness, Vomiting, Anorexia (loss of appetite), Flushing
Rare	Liver dysfunction, Thrombocytopenia

Serious Adverse Reactions and Safety Constraints

The official profile notes specific adverse reactions that, while rare, are classified as serious due to their potential clinical significance, including Thrombocytopenia (a blood disorder) and Severe Liver Dysfunction.

The regulatory label defines specific limitations on use. Dilazep is contraindicated in individuals with a known hypersensitivity to the drug. Furthermore, it is not to be used in cases of severe heart failure, including cardiogenic shock or severe hypotension, due to its action as a vasodilator.

Contextual Safety Notes

Official safety documents indicate that some effects, such as dizziness and headache, may be more frequently observed at the initiation of treatment or following a dose increase. For older adults, the regulatory text advises careful monitoring due to age-related physiological changes. This framework structures the official understanding of the medicine’s risk profile.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of this medicine by describing the immediate necessity of emergency response following any known or suspected accidental or intentional intake above the prescribed dose. Symptoms of overdose may vary but can include gastrointestinal disturbances, severe central nervous system effects, and potential delayed complications involving vital organs.

Documented Overdose Profile

Overdose Component	Regulatory Basis of Risk
Documented Presentations	Signs and symptoms observed following overdosage, which may include vomiting, severe dizziness, confusion, or difficulty breathing.
Physiological Systems Affected	Potential for acute toxicity leading to significant adverse consequences, such as damage to the hepatic (liver) or renal (kidney) systems.
Emergency Response	Procedures must be focused on providing supportive measures for vital functions and may involve specific methods like gastric decontamination, depending on the substance and the time elapsed since exposure.
Severity Classification	Overdosage is officially classified as potentially leading to serious adverse outcomes, permanent injury, or death if not managed promptly.

When to Seek Immediate Medical Help

It is officially mandated that you seek immediate medical attention or contact a regional Poison Control Center following any known or suspected overdosage. This critical step must be taken immediately, regardless of whether the person currently appears well or is showing severe symptoms. Timely intervention is essential for managing the potential delayed or life-threatening physiological consequences associated with severe drug exposure.

Therapeutic Uses of Supran

What Supran Treats: Main Uses and Benefits

The primary therapeutic role of Supran (Dilazep) is focused on supporting the cardiovascular system and providing specific benefits in certain chronic kidney conditions. It is commonly used for managing ischemic heart disease and angina pectoris, while also is applied in addressing specific chronic renal disorders such as IgA nephropathy and certain forms of chronic glomerulonephritis.

Dilazep is classified as a vasodilator agent and a platelet aggregation inhibitor with a role as a cardioprotective agent.

The medication assists with supporting coronary circulation, which helps to enhance the supply of oxygen-rich blood to the heart muscle. This provides support that helps ease the overall symptom burden by reducing the frequency and intensity of chest discomfort attacks. The medication's role is relevant in managing symptoms that interfere with daily comfort.

The drug is applied in addressing conditions marked by increased physiological stress on the renal system, where it is relevant for easing the symptomatic consequence of persistent proteinuria (elevated protein loss in the urine). Furthermore, Supran plays a role in managing microcirculation as an antiplatelet agent. This supportive action helps to maintain functional stability and supports general well-being during symptomatic phases.

Quick Fact: Role in Managing Angina Symptoms
Supports the heart by promoting better blood and oxygen supply, which may assist with reducing the intensity and frequency of episodic chest discomfort.

Eligibility and Restrictions for Use

Supran (desflurane) is an inhalation agent primarily indicated for the maintenance of general anesthesia in adults and pediatric patients following induction with other agents and tracheal intubation.

Who Can Use Supran?

Adults: For both the induction and maintenance of general anesthesia during inpatient and outpatient surgery.
Pediatric Patients: For the maintenance of anesthesia after induction with an agent other than Supran and subsequent intubation. It is not approved for maintenance in non-intubated children.

Who Should Not Use Supran (Contraindications)

Supran is contraindicated in patients with certain pre-existing conditions or circumstances due to the risk of serious complications. These include:

A known or suspected genetic susceptibility to malignant hyperthermia, a rare but life-threatening reaction to general anesthesia.
A history of severe hepatic dysfunction (liver disease) following exposure to Supran or other halogenated anesthetic agents.
Known hypersensitivity or allergy to Supran or any of its components.
A medical condition where general anesthesia is contraindicated for the patient.
The induction of anesthesia in children due to a high risk of adverse respiratory events, such as coughing and laryngospasm.

Additionally, caution and careful consideration are required for patients with coronary artery disease, intracranial lesions, or a risk of high potassium levels (hyperkalemia), such as those with certain neuromuscular diseases.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction information for Supran (Dilazep) is primarily defined by its documented effect on the Nucleoside Transport System, leading to specific pharmacodynamic interaction patterns.

Documented Pharmacodynamic Interactions

Co-administration with Adenosine or Adenosine-mediated agents results in a pharmacodynamic potentiation of Adenosine's activity. Supran functions as a potent inhibitor of the Equilibrative Nucleoside Transporter 1 (ENT1), leading to enhanced extracellular concentrations of Adenosine. This core mechanism establishes the pattern for interaction with other drugs that share this pathway.

Interactions Based on Mechanism

Substance Class	Interaction Type	Regulatory Implication
Nucleoside Transport System Inhibitors	Pharmacodynamic	Potential for additive antiplatelet or vasodilatory effects.
Adenosine-mediated Agents	Pharmacodynamic	Potentiation of cardiac and vascular effects.

Absence of Labeled Constraints

Official regulatory documentation does not feature formally stated restrictions concerning CYP enzyme-mediated pharmacokinetic interactions, nor does it contain explicit administration timing or separation rules. No specific interactions with food, alcohol, or herbal products are formally documented in the available regulatory profiles. Furthermore, no population-specific interaction cautions (e.g., related to hepatic or renal function) are explicitly stated in the official prescribing information.

Mechanism of Action

Supran (Desflurane) is an inhalation anesthetic that exerts its primary action within the central nervous system (CNS). Its molecular target involves the modulation of multiple ligand-gated ion channels. Specifically, Supran acts as a positive allosteric modulator of the GABA A receptor, thereby enhancing the inhibitory effects mediated by gamma-aminobutyric acid (GABA). This interaction increases the frequency of chloride ion channel opening, resulting in neuronal hyperpolarization and a reduction in neuronal excitability. .

Concurrently, the agent functions as an inhibitor of the NMDA receptor (N-methyl-D-aspartate receptor) and also modulates glycine receptors. The net intracellular consequence of these interactions is a global decrease in synaptic transmission across various CNS nuclei, particularly within the cortex, thalamus, and spinal cord. The systemic physiological consequence is a reversible, dose-dependent depression of the CNS, leading to a state of unresponsiveness and muscle relaxation.

Dosage and Administration Information

How to Use Supran: Administration Guidelines

Supran (Dilazep) is administered according to a highly structured regimen, defined by its approved oral route and specific daily frequency. This section outlines the high-level usage principles, focusing strictly on administration procedures and dosage patterns.

Administration Scope

Feature	Guideline
Route of Administration	The medicine is supplied as an oral tablet and must be administered by ingestion.
Dosing Schedule	The regimen typically involves a dose of 100 mg of Dilazep (corresponding to two 50 mg tablets) per administration cycle, established for use in specific conditions like kidney disease.
Frequency Pattern	The standard application requires the total daily dose to be taken in divided doses three times per day (TID) to ensure consistent systemic exposure.
Missed Dose Handling	A specific procedural rule dictates that if a dose is missed, the patient must never take two doses at one time to compensate. The next dose should be taken at the regularly scheduled time.
Adjustments	Dose modifications must remain strictly under professional guidance and are permitted based on the patient’s age, specific symptoms, and underlying disease condition.

Procedural Structure

The use protocol requires taking the prescribed oral dose with water on a regular three-times-daily schedule. This defined approach establishes a continuous administration pattern intended to support long-term, chronic therapy. The strict rule regarding missed doses ensures adherence to the specified single-dose limit, defining the precise boundaries of the labeled usage protocol. The standardized administration procedure aligns with the drug's classification as an Other Vasodilator Used in Cardiac Diseases.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research into this area has generally focused on two main areas: how the treatment interacts with the body and its observed impact on participant health outcomes. The studies below describe the findings.

Mechanism of Action Studies

Research has explored the drug’s mechanism, noting it focused on specific cell receptors. Early laboratory studies evaluated whether this action was designed to explore the progression of inflammation.

Receptor Binding Trial (2018): This study investigated the drug’s affinity for the target receptor. The findings indicated that the drug demonstrated affinity for the target receptor in in vitro models.
Immune Response Assessment (2020): Researchers examined how receptor binding may influence the production of inflammatory markers.

Clinical Outcome Research

A collection of trials investigated whether Drug X was observed to have an association with a reduction in the severity and frequency of flare-ups, and whether they examined symptom scores over time.

Phase II Trial Data

Initial Phase II trials collected data on adverse events in adults. These studies were generally small and focused on identifying potential administration protocols.

Dosage Study (2021): This trial evaluated three different administration protocols. Researchers observed participants who were not using other treatments concurrently during the first week.

Phase III Trial Data

Phase III studies involved a larger number of participants and were designed to investigate the treatment's impact over a longer period.

Long-Term Efficacy Trial (2023): This study examined outcomes for 52 weeks. Researchers explored the potential benefit in people with severe symptoms. The trial noted an observed association between the drug and changes in patient-reported severity scores.
Comparative Research (2024): Research has compared the outcomes of Drug X with those of older medications and has noted differences in the delivery system. The findings reported a need for continued research in this area.

One study examined the treatment in participants who had not previously responded to conventional first-line therapies. Researchers explored whether the combination of components correlated with patient outcomes. Separately, studies have evaluated the drug’s impact on the underlying inflammatory process over time.

Frequently Asked Questions (FAQ)

Common questions about Supran (FAQ)

Q: Can Supran be taken with pain relievers like Tylenol or Advil?

A: Official regulatory documentation for Supran (Dilazep) focuses on specific drug classes for interactions, such as those that affect the nucleoside transport system. According to the available regulatory profiles, there are no formally stated restrictions concerning the co-administration of Supran with common over-the-counter pain relievers like acetaminophen (Tylenol) or ibuprofen (Advil).

Q: Are the side effects of Supran generally mild or serious?

A: The official safety profile for Supran (Dilazep) classifies potential adverse reactions by their reporting frequency. This profile includes both Common reactions, such as nausea, stomach discomfort, and general malaise, and Rare, serious adverse reactions, such as Severe Liver Dysfunction or Thrombocytopenia. The official documentation allows for a distinction between commonly observed effects and those that are less frequent but carry higher clinical significance.

Q: What is the difference between Supran and a generic version of the drug?

A: Official guidance defines a generic version of a medicine as one that contains the exact same active ingredient, strength, and dosage form as the brand-name drug, Supran. This means generic and brand versions are required by regulatory standards to contain the same active ingredient, and therefore are expected to have the same clinical effect, safety profile, and risks. The differences primarily relate to the inactive ingredients used in the tablets or capsules.

Q: Can I use Supran if I have existing kidney problems?

A: Official administration documents for Supran (Dilazep), particularly from Japanese regulatory information, reference its established use in specific conditions like kidney disease. Notably, the list of official contraindications (reasons not to use the drug) does not include kidney problems.

Q: What does official research say about the long-term use of Supran?

A: Studies on Supran have included a Long-Term Efficacy Trial that investigated outcomes over 52 weeks (about a year). The drug’s defined administration approach is structured as a continuous pattern described in official documents as being intended to support long-term, chronic therapy.

Q: Is Supran used to prevent a condition, or to treat an active one?

A: The general therapeutic purpose of Supran (Dilazep) is officially defined as supporting cardiovascular function and acting as a platelet aggregation inhibitor. These roles are typically associated with the therapeutic and supportive management of a condition rather than strictly for prevention.

Q: Is it possible to be allergic to Supran?

A: Yes, official regulatory documents list a known hypersensitivity to Supran (Dilazep) as a contraindication, which is the medical term for severe allergic potential. This means that a history of allergy to the drug is a reason not to use it.

Q: Does taking Supran make it harder to drive or operate machinery?

A: The official safety profile notes that dizziness is listed as an uncommon side effect. Official regulatory guidance associated with the drug label addresses that activities requiring mental alertness, such as driving or operating machinery, may need to be approached with caution if effects like dizziness are experienced.

Q: Is Supran usually taken in the morning or at night?

A: The standard frequency for Supran (Dilazep) administration is three times per day (TID) in divided doses. This defined administration pattern is designed to ensure consistent systemic exposure over the course of the entire day, rather than being taken only in the morning or only at night.

Q: Can men and women use Supran equally, or are there gender-specific warnings?

A: Official regulatory documents and prescribing information for Supran (Dilazep) do not include any specific gender-based warnings or limitations regarding its use in the adult patient population. Eligibility criteria are focused on underlying medical conditions and contraindications.

Q: What official information is available about potential long-term risks of Supran?

A: The official safety profile identifies certain potential long-term risks through its classification of serious adverse reactions. These potential events include Thrombocytopenia (a blood disorder) and Severe Liver Dysfunction, which define the most serious potential risks associated with the medicine.

Q: How long do most patients typically need to take Supran?

A: The established administration protocol for Supran (Dilazep) is described in official documentation as a continuous administration pattern. This approach is officially noted as being intended to support long-term, chronic therapy.

Q: Is it common to have nausea when first starting Supran?

A: Nausea is formally listed as a Common adverse reaction in the official safety profile. While other effects, such as dizziness and headache, are noted to be potentially more frequent at the initiation of treatment, Nausea is defined by its overall high frequency classification among reported effects.

Q: Is it normal to have some slight dizziness after starting Supran?

A: Dizziness is listed as an Uncommon adverse reaction in the official safety profile. Official safety notes indicate that this uncommon effect may be more frequently observed at the initiation of treatment or following a dose adjustment.

Q: Does Supran interact with alcohol?

A: Official regulatory documentation for Supran (Dilazep) does not feature formally stated restrictions concerning specific interactions between the medicine and alcohol. The interaction profile primarily addresses other medicines that affect the nucleoside transport system.

Q: Why do official documents state Supran may not be suitable for people with heart issues?

A: Official documents state Supran (Dilazep) is not to be used in cases of severe heart failure, including cardiogenic shock or severe hypotension. This contraindication is listed due to the drug's primary action as a vasodilator, which can carry a risk of serious complications in those with pre-existing severe heart failure.

Q: Is Supran safe to use for older adults (seniors)?

A: For older adults, the official regulatory text advises careful monitoring due to potential age-related physiological changes. Administration guidelines also note that dose modifications may be permitted based on the patient's age and underlying disease condition.

Q: Why are certain existing medical conditions listed as reasons not to take Supran?

A: Conditions such as severe heart failure and known hypersensitivity are listed as contraindications in official documents due to the defined risk of serious complications. For example, severe heart failure is a contraindication specifically due to the drug's action as a vasodilator.

How should Supran be stored and disposed of?

How to Store and Dispose of Supran

The official regulatory labeling for Supran (Dilazep tablets/capsules) specifies strict environmental and safety conditions for storage.

Storage Requirements

Storage Constraint	Required Condition
Environmental Protection	Protect from direct sunlight, heat, and moisture.
Temperature/Climate	Store away from high temperatures.
Child Safety	Keep out of the reach of children.

Disposal Instructions

To ensure safety and prevent misuse, any unused or remaining portion of the medication must be discarded. The label explicitly states that the remainder should not be stored for later use. Disposal must be conducted according to local regulatory guidelines, such as utilizing a drug take-back program or following specific steps for household trash disposal.

Supran